Pharma’s reputation problem goes beyond pricing – people don’t know what it stands for

Matthew Hare-Scott argues that renewed attacks on the industry from politicians have much to do with pharma losing sight of its purpose.

As Jeremy Corbyn addressed the audiences at this year’s Labour Annual Party Conference, he made a pledge to create a nationalised drugs manufacturer to create generic versions of drugs that the NHS could not afford. While aimed at the party faithful (which arguably grew smaller following the Tom Watson debacle) the announcement grabbed the attention of many across media, healthcare and business.